Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 8:51:97-99.
doi: 10.1016/j.jdcr.2024.06.033. eCollection 2024 Sep.

Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure

Alice Sohn  1 , Nicole Bouché  2 , George Michael Lewitt  3 , Eingun James Song  1
Affiliations
Case Reports

Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure

Alice Sohn et al. JAAD Case Rep. .
No abstract available

Keywords: Medical Dermatology; biologics; clinical research; dermatomyositis; drug response; general dermatology; immunodermatology; upadacitnib.

PubMed Disclaimer

Conflict of interest statement

Dr Lewitt reports relationship with AbbVie, Amgen, Lilly, Janssen, Orthodermatologics, UCB, Novartis, Pfizer, Dermavant, Bristol Myers Squibb, Incyte, Arcutis, Sol-Gel, AoBiome, Galderma Laboratories, Leo, Novan, Derm-Tech, and Dermata-Therapeutics; Dr Song reports relationship with BMS, AbbVie, Eli Lilly, Janssen, Novartis, UCB, Pfizer, Amgen, Dermavant, Arcutis, Incyte, SUN, Boehringer Ingelheim, Sanofi & Regeneron, and Ortho-dermatologics. Drs Sohn and Bouché have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Initial presentation before treatment.
Fig 2
Fig 2
Hematoxylin and eosin (10× magnification) demonstrating a mild lichenoid lymphocytic infiltrate with prominent interface vacuolar change.
Fig 3
Fig 3
Three months after treatment with upadacitinib 30 mg daily.
See this image and copyright information in PMC

References

    1. Paik J.J., Lubin G., Gromatzky A., Mudd P.N., Ponda M.P., Christopher-Stine L. Use of JAK inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2023;41(2):348–358. doi: 10.55563/clinexprheumatol/hxin6o. - DOI - PMC - PubMed
    1. Somani A.K., Swick A.R., Cooper K.D., McCormick T.S. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008;144(10):1341–1349. doi: 10.1001/archderm.144.10.1341. - DOI - PMC - PubMed
    1. Ang P.S., Ezenwa E., Ko K., Hoffman M.D. Refractory dermatomyositis responsive to anifrolumab. JAAD Case Rep. 2023;43:27–29. doi: 10.1016/j.jdcr.2023.10.023. - DOI - PMC - PubMed
    1. Baechler E.C., Bilgic H., Reed A.M. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther. 2011;13(6):249. doi: 10.1186/ar3531. - DOI - PMC - PubMed
    1. Min M.S., Alsarheed A., Kassamali B., et al. Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers. J Am Acad Dermatol. 2022;86(2):423–425. doi: 10.1016/j.jaad.2021.07.003. - DOI - PubMed

Publication types

LinkOut - more resources